Nanosonics Limited · ASX:NAN
Nanosonics — H1 FY2016 Earnings Presentation
19 slides from Nanosonics's earnings presentation, Mar 1, 2016
Slide 1: Nanosonics Limited 2016 Half Year Results
For personal use only Nanosonics Limited 2016 Half Year Results Investor Presentation Michael Kavanagh CEO & President McGregor Grant Chief Financial Officer
Slide 2: Disclaimer
For personal use only Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, fina
Slide 3: Corporate Mission
For personal use only Corporate Mission We improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted, and introducing innovative technologies that deliver improved standards of care. Johns Hopkins Phot
Slide 4: Corporate objectives
Corporate objectives For personal use only Customer Experience Establish our offerings as new standards of care globally and provide customers a convenient, seamless and consistent experience with both product and brand. Product Innovation Operational Excellence People Engagement Create and bring to
Slide 5: Company Overview
For personal use only Company Overview • Proprietary automated technology for low Key Corporate Data temperature, high level disinfection Share price* $1.87 • First product, trophon® EPR, for high level Shares on issue* 283.51 million disinfection of ultrasound probes Market capitalisation* $530 mil
Slide 6: 2016 H1 Highlights
2016 H1 Highlights For personal use only • First full half under new North American direct operations delivers record sales of $15.5 million. • Installed base in North America increased by over 1,700 units in half with total installed base now in excess of 6,700 units. • Publication of HPV study dem
Slide 7: 2016 H1 Financial Results
For personal use only 2016 H1 Financial Results Sales $21.5 $22.2 • Record sales of $15.6 million under $ million first full half operating with new North H1 H2 $14.9 $7.9 $15.6 American business model. $11.8 $12.3 • No trophon unit sales to GE $10.5 Healthcare in North America in period $7.2 $14.3
Slide 8: Excellent growth momentum under new North American business model
Excellent growth momentum under new North For personal use only American business model Quarterly Sales • Steady growth over the past $ million four quarters following the announcement of North American direct operations – FY15 Q3 – Announced new business model $9.1 – FY15 Q3 / Q4 – Established $8.3
Slide 9: Trophon becoming standard of care in North America
Trophon becoming standard of care in North For personal use only America • Installed base increased by over 1,700 units in H1 FY16 • There are now more than 6,700 trophon EPR systems in operation across 2,000 facilities including 44 of top 50 hospitals • Estimated market opportunity in excess of 40,
Slide 10: Regional Highlights
For personal use only Regional Highlights Europe UK awaiting guidelines from England and Scotland (expected Q4). Pipeline growing strongly in anticipation of guidelines. 25 NHS trusts (46 hospitals) already adopted trophon. 9 of the 25 have followed up initial purchase with additional units We
Slide 11: 2016 Financial Results
For personal use only 2016 Financial Results FY16 FY15 FY14 • Sales up 8.6% to $15.6 million – In line with plan as North American direct sales fully operational $ million H1 H1 H2 FY15 H1 H2 FY14 • Gross Profit up $3.4 million to $12.6 million Sales Revenue 15.6 14.3 7.9 22.2 9.7 11.8 21.5 • GP% 81
Slide 12: Fundamentals for adoption continue to strengthen.
For personal use only Fundamentals for adoption continue to strengthen. The Hospital-Acquired Condition (HAC) Reduction Program1 The Joint Commission Non compliance with infection control standards associated with medical equipment & devices is one of the top 5 findings by The Joint Commission2 CDC
Slide 13: HPV – A real risk of cross contamination through ultrasound examination
HPV – A real risk of cross contamination through For personal use only ultrasound examination - For patients AND staff • “a considerable number of ultrasound probes contaminated with human and HR-HPV DNA, despite LLD disinfection and probe cover”1 • A substantial 1 persistence of microorganisms obse
Slide 14: trophon EPR first and only system to kill HPV
For personal use only trophon EPR first and only system to kill HPV • 2014 study showed disinfectants commonly used on ultrasound probes not effective against human papillomavirus (HPV)1 • Second study demonstrated that trophon EPR is the first and only system proven to kill high-risk, cancer-causin
Slide 15: Why is trophon being adopted as Standard of Care?
Why is trophon® being adopted as Standard For personal use only of Care? Reduces the risk of ultrasound HAIs Extensive clinical validation Only system proven to kill HPV Simpler to use with consistent results Creates a safer environment for patients & staff No exposure to harmful chemicals o
Slide 16: Compatible with more than ultrasound transducer models
Compatible with more than 950 ultrasound transducer For personal use only models • Covers all world’s leading manufacturers • Includes both intracavitary and surface probes
Slide 17: R&D investment
For personal use only R&D investment • $3.3 million in half invested in R&D activities across mechanical, electrical and software engineering, microbiology and chemistry • Active programs underway on: – Next generation trophon – New decontamination devices – New disinfectant chemistries
Slide 18: Business Outlook – Positive momentum continues
Business Outlook – Positive momentum For personal use only continues • Direct North American sales operations in place and delivering encouraging results. • Becoming standard of care in North America with >6700 units installed. • New supporting guidelines expected in UK, France and Japan • Expansion
Slide 19: For personal use only
a) © AjUO esn jeuosied JOS